Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations
A. Vargas Hernandez, E. M. Mace, O. Zimmerman, C. Zerbe, A. Freeman, S. Rosenzweig, J. W. Leiding, T. Torgerson, M. C. Altman, E. Schussler, C. Cunningham-Rundles, I. K. Chinn, I. C. Hanson, N. L. Rider, S. M. Holland, , L. R. Forbes
This study shows that ruxolitinib partially restores NK cell function in STAT1 GOF patients by reducing STAT1 phosphorylation and improving cytotoxic activity.
bioRxiv · Jun 28, 2017Immunology